About Us:
Foundation News
About Us: Foundation News
The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics have entered a new collaboration focused on regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders. Recent FDA approvals of several disease modifying therapies for SMA has made regenerative medicine approaches the next frontier in drug discovery and development. The SMA Foundation-PTC…
The Spinal Muscular Atrophy (SMA) Foundation, a non-profit, organization whose mission is to accelerate the development of treatments for SMA, the leading cause of genetic death in young children, visited the Nasdaq MarketSite in Times Square on August 17, 2018. In honor of the occasion, Dinakar Singh, Co-Founder and Chairman of the Board of Directors,…
CombinatoRx Inc. of Boston has inked a multimillion-dollar, two-year research and development deal with a foundation to find treatments for spinal muscular atrophy, a neuromuscular disease. The Boston startup said its deal with the New York-based Spinal Muscular Atrophy Foundation calls for two years of research and development funding from the foundation. CombinatoRx will also…
Curis Inc., a Cambridge-based drug developer, received a $5.4 million three-year grant to help treat spinal muscular atrophy, the company announced Tuesday. The Spinal Muscular Atrophy Foundation awarded the grant to Curis to identify therapeutic compounds that could be used to treat the neuromuscular disease, which is the leading genetic cause of infant and toddler…
Curis Inc. in Cambridge has received a $5.4 million, three-year grant from the Spinal Muscular Atrophy Foundation to identify therapeutic compounds to treat spinal muscular atrophy, a debilitating neuromuscular disease that is the leading genetic cause of infant and toddler death. The study will use proprietary Curis technologies and expertise to develop and refine motor…
New York, NY – April 19, 2004 – The Spinal Muscular Atrophy Foundation today announced that it has awarded new research grants totaling $1.125 million to four outstanding Young Investigators specializing in research on Spinal Muscular Atrophy (SMA), the leading genetic killer of infants and toddlers. These grants support the implementation and advancement of clinical research…
ANN ARBOR, Mich. — Sept. 15, 2008 – Assay Designs and the Spinal Muscular Atrophy Foundation (SMAF) are very pleased to announce a collaborative agreement for development of reagents and assays for SMN (Survival Motor Neuron) protein to expedite drug discovery and development efforts for spinal muscular atrophy (SMA), the leading genetic cause of mortality in…